By Counterforce Health Team in Krystexxa (pegloticase) —

How to Get Krystexxa (Pegloticase) Covered by UnitedHealthcare in Texas: Complete Timeline and Appeals Guide

Answer Box: Getting Krystexxa Covered by UnitedHealthcare in Texas

UnitedHealthcare requires prior authorization for Krystexxa (pegloticase) with strict step therapy and documentation requirements. The standard approval timeline is 15 days for complete submissions, with expedited reviews decided within 24 hours for urgent cases. To start: gather evidence of failed allopurinol and febuxostat trials, obtain G6PD testing results, and ensure your rheumatologist submits the PA request through OptumRx with comprehensive clinical documentation. If denied, Texas allows internal appeals within 180 days and external review through the Texas Department of Insurance.

Table of Contents

  1. What Affects Krystexxa Approval Timing
  2. Pre-Submission Preparation (0-2 Days)
  3. Submission to Initial Review (1-5 Days)
  4. Additional Information Requests (1-7 Days)
  5. Decision Window and Outcomes
  6. If Denied: Appeal Process in Texas
  7. Renewal Cycles and Maintenance
  8. Timeline Overview Table
  9. Time-Saving Tips for Faster Approval
  10. FAQ

What Affects Krystexxa Approval Timing

Several factors influence how quickly UnitedHealthcare processes your Krystexxa prior authorization in Texas:

Benefit Type: OptumRx manages most UnitedHealthcare pharmacy benefits, including specialty drugs like Krystexxa. The standard review timeline is 15 days for complete submissions.

Documentation Completeness: Missing step therapy documentation, G6PD test results, or inadequate clinical notes are the most common causes of delays. UnitedHealthcare's commercial policy requires extensive evidence of conventional therapy failures.

Prescriber Specialty: Requests from rheumatologists typically process faster than those requiring specialty verification from other providers.

Pre-Submission Preparation (0-2 Days)

Essential Documentation Checklist

Before submitting your prior authorization, gather these required documents:

  • G6PD Deficiency Test: Mandatory screening result showing no G6PD deficiency (Krystexxa is contraindicated if positive)
  • Step Therapy Documentation: Evidence of failed trials with both allopurinol and febuxostat at maximum tolerated doses for ≥3 months
  • Serial Uric Acid Levels: Lab results showing persistent levels >6 mg/dL despite conventional therapy
  • Clinical Records: Documentation of continued gout symptoms, tophi measurements, flare history
  • Provider Letter: Medical necessity letter from rheumatologist with ICD-10 code M1A.9
Tip: Start gathering documentation 2-3 weeks before your planned treatment start date to avoid delays.

Coding Requirements

Krystexxa uses J2507 billing code (per 1 mg), with each 8 mg vial requiring 8 units. Ensure your provider includes proper place of service and administration codes for infusion therapy.

Submission to Initial Review (1-5 Days)

How to Submit

Primary Method: Use the OptumRx provider portal for fastest processing.

Alternative Methods:

  • Fax: 1-866-434-5523 (for supporting documentation)
  • Phone: 1-800-711-4555 (OptumRx prior authorization)
  • CoverMyMeds platform for electronic submissions

What Reviewers Check First

OptumRx reviewers prioritize these elements during initial screening:

  1. Prescriber Qualification: Must be rheumatologist or nephrologist
  2. Step Therapy Compliance: Clear documentation of allopurinol and febuxostat failures
  3. Safety Screening: G6PD test results and contraindication assessment
  4. Clinical Justification: Evidence of refractory chronic gout with ongoing symptoms

Additional Information Requests (1-7 Days)

If UnitedHealthcare requests additional information, respond within 7 days to avoid processing delays. Common requests include:

  • More detailed medication trial histories with specific dates and dosages
  • Recent uric acid lab values (within 30 days)
  • Comprehensive rheumatology consultation notes
  • Documentation of tophus measurements or joint imaging
Note: Incomplete responses restart the review clock, potentially adding 2-3 weeks to your approval timeline.

Decision Window and Outcomes

Standard Timeline

  • Approval: Typically issued within 15 days of complete submission
  • Denial: Includes specific reasons and required next steps
  • Partial Approval: May include quantity limits or site-of-care restrictions

Reading Your Approval Letter

Approved requests will specify:

  • Authorized quantity (typically 8 mg every 2 weeks)
  • Duration of coverage (usually 6-12 months)
  • Site of care requirements (hospital outpatient, infusion center)
  • Renewal requirements and timeline

If Denied: Appeal Process in Texas

Internal Appeals

Filing Deadline: Within 180 days of denial notice Decision Timeline:

  • Standard appeals: 30 days for pre-service requests
  • Expedited appeals: 24 hours for urgent cases where delay would jeopardize health

Expedited Review Criteria

Request expedited review if:

  • Current gout flares are severe and frequent
  • Delay would cause irreversible joint damage
  • Patient has contraindications to alternative therapies

External Review Through Texas DOI

If internal appeals fail, Texas residents can request external review through an Independent Review Organization (IRO):

Filing Deadline: Within 4 months of final internal denial Decision Timeline:

  • Standard external review: 20 days
  • Expedited external review: 5 days

Contact Information:

  • Texas Department of Insurance: 1-800-252-3439
  • IRO Information Line: 1-866-554-4926

Required Appeal Documentation

Include these elements in your appeal:

  • Complete denial letter and member ID
  • Updated clinical notes showing ongoing medical necessity
  • Peer-reviewed literature supporting Krystexxa use
  • Statement of how denial impacts patient health

At Counterforce Health, we help patients and clinicians turn insurance denials into successful appeals by creating targeted, evidence-backed rebuttals that align with each payer's specific criteria. Our platform streamlines the complex appeals process, ensuring you have the strongest possible case for coverage.

Renewal Cycles and Maintenance

Reauthorization Timeline

UnitedHealthcare typically requires reauthorization every 6-12 months for Krystexxa. Submit renewal requests at least 30 days before expiration to avoid treatment gaps.

Renewal Requirements

  • Serial uric acid levels from all infusions (no two consecutive levels should exceed 6 mg/dL)
  • Documentation of clinical benefit (fewer flares, reduced tophi, improved function)
  • Continued safety monitoring compliance
  • Updated treatment plan for next 6 months
Critical: Never use allopurinol or febuxostat to bridge coverage gaps, as this can mask treatment failure and increase reaction risks upon restart.

Timeline Overview Table

Phase Timeline Key Actions Potential Delays
Pre-submission 0-2 days Gather documentation, verify G6PD testing Missing step therapy records
Initial submission 1-5 days Submit via OptumRx portal or fax Incomplete forms
Review process 15 days (standard) OptumRx clinical review Additional information requests
Decision notification 1-2 days Approval/denial letter issued System processing delays
Internal appeal 30 days (standard)
24 hours (expedited)		 Submit appeal with new evidence Missing documentation
External review 20 days (standard)
5 days (expedited)		 Texas DOI IRO review Procedural errors

Time-Saving Tips for Faster Approval

Use Electronic Submissions

The OptumRx provider portal and CoverMyMeds platform process requests faster than fax submissions and provide real-time status updates.

Bundle All Evidence Upfront

Submit comprehensive documentation with your initial request rather than waiting for additional information requests. This includes:

  • Complete medication trial history with dates and outcomes
  • All relevant lab results from the past 6 months
  • Detailed rheumatology consultation notes
  • G6PD screening results

Leverage Specialty Pharmacy Partnerships

Work with specialty pharmacies experienced in Krystexxa prior authorizations. They often have established relationships with OptumRx reviewers and understand common approval requirements.

Monitor Submission Status

Check your request status daily through the provider portal and respond immediately to any information requests to avoid processing delays.

For complex cases or repeated denials, Counterforce Health can help create targeted appeals that address specific UnitedHealthcare criteria and improve your chances of approval.

FAQ

How long does UnitedHealthcare prior authorization take for Krystexxa in Texas? Standard prior authorization decisions are made within 15 days of complete submission. Expedited reviews for urgent cases are completed within 24 hours.

What if Krystexxa is not on my UnitedHealthcare formulary? Krystexxa requires prior authorization regardless of formulary status. Non-formulary drugs may require additional step therapy documentation and appeals.

Can I request an expedited appeal in Texas? Yes, if delay would seriously jeopardize your health or ability to regain function. Expedited appeals must be decided within 24 hours under Texas regulations.

Does step therapy apply if I failed treatments outside Texas? Yes, UnitedHealthcare accepts documentation of failed conventional therapies regardless of where treatment occurred, provided records are complete and verifiable.

What happens if UnitedHealthcare doesn't respond within the required timeframe? Under Texas law, failure to respond to expedited appeals within 24 hours results in automatic approval of the request.

Who can prescribe Krystexxa for UnitedHealthcare coverage? UnitedHealthcare requires prescriptions from rheumatologists or nephrologists. Other specialists may need additional justification.

How often do I need reauthorization for Krystexxa? Reauthorization is typically required every 6-12 months, depending on your specific plan. Submit renewal requests 30 days before expiration.

What if my G6PD test is positive? G6PD deficiency is an absolute contraindication for Krystexxa due to severe hemolysis risk. Alternative gout treatments would be considered instead.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and circumstances. Always consult with your healthcare provider and insurance plan for specific guidance regarding your situation. For assistance with complex prior authorization and appeals processes, contact the Texas Department of Insurance at 1-800-252-3439.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.